Sendai virus for cancer immunotherapy

Yasuji Ueda, Mamoru Hasegawa, Yoshikazu Yonemitsu

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Dendritic cells (DCs) have a crucial role to play in fighting nonself organisms and cells, including tumors. Clinically, numerous DC vaccinations have been attempted for cancer immunotherapy since the first trial, published in 1995, but with limited success. We found that Sendai virus (SeV) vector infection induces maturation of DCs and produces more powerful antitumor immunity against DCs in mouse models. We used a SeV vector as an immune booster for tumors and believe that this novel therapy, designated as immunostimulatory virotherapy, will offer potent treatment for tumors.

Original languageEnglish
Title of host publicationViral Applications of Green Fluorescent Protein
Subtitle of host publicationMethods and Protocols
PublisherHumana Press Inc.
Pages299-308
Number of pages10
ISBN (Print)9781934115879
DOIs
Publication statusPublished - Jan 1 2009
Externally publishedYes

Publication series

NameMethods in Molecular Biology
Volume515
ISSN (Print)1064-3745

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Sendai virus for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this